Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients

Carolina Cubillos-Zapata, Miguel Ángel Martínez-García, Francisco Campos-Rodríguez, Manuel Sánchez de la Torre, Eduardo Nagore, Antonio Martorell-Calatayud, Luis Hernández Blasco, Eusebi Chiner Vives, Jorge Abad-Capa, Josep María Montserrat, Valentín Cabriada-Nuño, Irene Cano-Pumarega, Jaime Corral-Peñafiel, Trinidad Diaz-Cambriles, Olga Mediano, María Somoza-González, Joan Dalmau-Arias, Isaac Almendros, Ramón Farré, Eduardo López-Collazo, David Gozal, Francisco García-Río

Source: Eur Respir J, 53 (2) 1801298; 10.1183/13993003.01298-2018
Journal Issue: February

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Carolina Cubillos-Zapata, Miguel Ángel Martínez-García, Francisco Campos-Rodríguez, Manuel Sánchez de la Torre, Eduardo Nagore, Antonio Martorell-Calatayud, Luis Hernández Blasco, Eusebi Chiner Vives, Jorge Abad-Capa, Josep María Montserrat, Valentín Cabriada-Nuño, Irene Cano-Pumarega, Jaime Corral-Peñafiel, Trinidad Diaz-Cambriles, Olga Mediano, María Somoza-González, Joan Dalmau-Arias, Isaac Almendros, Ramón Farré, Eduardo López-Collazo, David Gozal, Francisco García-Río. Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. Eur Respir J, 53 (2) 1801298; 10.1183/13993003.01298-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea
Source: Eur Respir J, 51 (3) 1701885; 10.1183/13993003.01885-2017
Year: 2018



Intermittent hypoxia increases melanoma metastasis to the lung in a mouse model of sleep apnea
Source: Annual Congress 2012 - Diagnostics in OSA: from polygraphy to genetics and cancer
Year: 2012

Association between sleep disordered breathing and aggressiveness markers of malignant cutaneous melanoma
Source: Eur Respir J 2014; 43: 1661-1668
Year: 2014



Circulating survivin levels in patients with obstructive sleep apnea
Source: International Congress 2017 – New pathophysiological insights: intermittent hypoxia, cardiopulmonary function and biomarkers
Year: 2017

Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome
Source: Eur Respir J 2006; 28: Suppl. 50, 414s
Year: 2006

Roles of periostin in patients with severe obstructive sleep apnea
Source: International Congress 2017 – New pathophysiological insights: intermittent hypoxia, cardiopulmonary function and biomarkers
Year: 2017

Coexistence of chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer and impact on survival
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017


Tumour infiltrating lymphocytes and tumour associated macrophages in chronic obstructive pulmonary disease (COPD) patients with non-small cell lung cancer (NSCLC) and in patients with NSCLC
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005

Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnoea
Source: Eur Respir J 2009; 33: 793-796
Year: 2009



The role of inflammatory biomarkers in obstructive sleep apnea syndrome
Source: International Congress 2018 – Sleep-disordered breathing: biomarkers and genetics and the role of hypoxia, insomnia, movement disorders and sleep quality
Year: 2018

Autoantibody against NBL1 in obstructive sleep apnea patients with cardiovascular disease
Source: International Congress 2017 – New insights into the understanding of sleep and the consequences of sleep apnoea
Year: 2017



Intermittent hypoxia enhances cancer progression in a mouse model of sleep apnoea
Source: Eur Respir J 2011; 39: 215-217
Year: 2012


Intermittent hypoxia enhances cancer progression in a mouse model of sleep apnoea
Source: Eur Respir J 2012; 39: 215-217
Year: 2012


Circulating cell-derived microparticles in patients with minimally symptomatic obstructive sleep apnoea
Source: Eur Respir J 2009; 33: 574-580
Year: 2009



Evaluation of thyroid function in patients with suspected obstructive sleep apnoea syndrome
Source: Annual Congress 2010 - Clinical aspects of sleep apnoea
Year: 2010


Impact of chronic obstructive pulmonary disease on the recurrence and second tumors of lung cancer after surgical resection
Source: International Congress 2019 – Asthma and COPD comorbidities
Year: 2019



Prevalence of thyroid disease in patients with obstructive sleep apnea
Source: Annual Congress 2011 - Obstructive sleep apnoea as a comorbidity
Year: 2011


The role of angiogenesis in obstructive sleep apnea (OSA)
Source: Eur Respir J 2005; 26: Suppl. 49, 357s
Year: 2005

Bilateral lung cancer with COPD or metastatic disease
Source: International Congress 2016 – CC4 Major challenges in thoracic surgical oncology
Year: 2016



Evaluation of sleep related breathing disorders and obstructive sleep apnea in patients with interstitial lung disease
Source: Annual Congress 2013 –Sleep disordered breathing in special situations II
Year: 2013